I-Lasofoxifene Tartrate CAS 190791-29-8 Chiral Purity ≥99.0% Purity ≥98.0% (HPLC) API High Purity

Inkcazelo emfutshane:

Igama leKhemikhali: Lasofoxifene Tartrate

CAS: 190791-29-8

Imbonakalo: Mhlophe ukuya kwi-Off-White Powder

Ukucoceka kweChiral: ≥99.0%Ubunyulu: ≥98.0% (HPLC)

Kunyango lwe-Postmenopausal Osteoporosis

Umgangatho ophezulu we-API, iMveliso yoRhwebo

Inquiry: alvin@ruifuchem.com

Thumela i-imeyile kuthi

Iinkcukacha zeMveliso

Iimveliso ezinxulumeneyo

Iithegi zeMveliso

Inkcazo:

Ubonelelo lwabavelisi ngoBusulungekileyo obuPhezulu kunye noMgangatho oZinzileyo
Igama leKhemikhali: Lasofoxifene Tartrate
CAS: 190791-29-8
I-Lasofoxifene Tartrate (CAS: 190791-29-8) kunyango lwe-Postmenopausal Osteoporosis

Iipropati zeMichiza:

Igama leMchiza	Lasofoxifene Tartrate
Izithethantonye	(5R,6S) -5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl) ethoxy]phenyl] -2-naphthalenol Tartrate Oporia
Inombolo yeCAS	190791-29-8
Inombolo yeCAT	RF-API20
Ubume beStokhwe	Kwi-Stock, iMveliso yeMveliso ukuya kumakhulu eeKilogram
Ifomula yeemolekyuli	C28H31NO2.ClH
Ubunzima beMolekyuli	450.019
Uphawu	Ruifu Chemical

Iinkcukacha:

Into	Iinkcukacha
Imbonakalo	Mhlophe ukuya kwi-Off-White Powder
Ukufuma (KF)	≤0.50%
Iintsimbi ezinzima	≤20ppm
Ucoceko lweChiral	≥99.0%
Ubunyulu / Indlela yokuHlalutya	≥98.0% (HPLC)
Ilahleko ekomisweni	≤0.50%
Intsalela kwi-Ignition	≤0.50%
Umgangatho woVavanyo	I-Pharmacopoeia yaseTshayina (CP);Umgangatho woShishino
Ukusetyenziswa	I-Active Pharmaceutical Ingredient (API);I-Postmenopausal Osteoporosis

Ukupakishwa kunye noGcino:

Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, igubu lekhadibhodi, 25kg/Igubu, okanye ngokwemfuno yomthengi.

Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ekukhanyeni, ukufuma kunye nokuhlaselwa zizinambuzane.

Izinto eziluncedo:

FAQ:

Isicelo:

I-Shanghai Ruifu Chemical Co., Ltd. ngumenzi ohamba phambili kunye nomthengisi weLasofoxifene Tartrate (CAS: 190791-29-8) enomgangatho ophezulu.
I-Lasofoxifene Tartrate isizukulwana sesithathu, i-non-steroidal ekhethiweyo ye-estrogen receptor modulator (SERM).Ibophelela ngokukhethekileyo kwi-ERalpha yomntu kunye nexabiso le-IC50 le-1.5 nM kwaye inqanda ukulahleka kwamathambo kwiigundane ze-ovariectomized.Kwizifundo zeklinikhi ze-postmenopausal osteoporosis, i-0.5 mg / imini ye-lasofoxifene idibaniswe neengozi ezincitshisiweyo ze-nonvertebral kunye ne-vertebral fractures, umdlavuza webele we-ER-positive, isifo senhliziyo, kunye ne-stroke kodwa ukwanda kwengozi yeziganeko ze-venous thromboembolic.I-Lasofoxifene nayo ibonakaliswe ukuba isebenze njenge-agonist ephikisanayo kwi-CB2 i-cannabinoid receptor, ebonisa amandla ayo okuphinda ahlaziywe njengonyango lwezibonakaliso apho i-CB2 ijoliswe kuyo.